Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by pabalooon Feb 16, 2020 12:55pm

88 Views

Post# 30697319

RE:RE:RE:RE:RE:RE:Sun Pharma Looking To Grab Isotrentinoin Market Share

Would expect absorbica licence to bring in around 6 million instead of the 2.6 million it currently brings in. With the advertising and new product launch including inventory I would expect a similar run as the last launch. That being said I would hope to retain a higher market share than the previous launch and hopefully hold closer to the 20%

Bullboard Posts

Opawica seeks drill permits for Bazooka Gold Targets in Abitibi